Sino Biopharmaceutical (FRA:SMZ1) Debt-to-EBITDA

: 1.64 (As of Jun. 2023)

View and export this data going back to . Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sino Biopharmaceutical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €1,356 Mil. Sino Biopharmaceutical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €133 Mil. Sino Biopharmaceutical's annualized EBITDA for the quarter that ended in Jun. 2023 was €909 Mil. Sino Biopharmaceutical's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 was 1.64.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Sino Biopharmaceutical's Debt-to-EBITDA or its related term are showing as below:

FRA:SMZ1' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.03 Med: 0.62 Max: 2.13
Current: 2.13

During the past 13 years, the highest Debt-to-EBITDA Ratio of Sino Biopharmaceutical was 2.13. The lowest was 0.03. And the median was 0.62.

FRA:SMZ1's Debt-to-EBITDA is ranked worse than
56.32% of 277 companies
in the Biotechnology industry
Industry Median: 1.39 vs FRA:SMZ1: 2.13

Sino Biopharmaceutical Debt-to-EBITDA Historical Data

The historical data trend for Sino Biopharmaceutical's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

1.17

2.03

0.61

1.93

2.13

Sino Biopharmaceutical Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial															0.69	1.53	3.05	1.64	2.65

Competitive Comparison

For the Biotechnology subindustry, Sino Biopharmaceutical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sino Biopharmaceutical Debt-to-EBITDA Distribution

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's Debt-to-EBITDA falls into.

Sino Biopharmaceutical Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sino Biopharmaceutical's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1316.652	+	576.569)	/	983.666
	=	1.92

Sino Biopharmaceutical's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1356.228	+	132.923)	/	909.494
	=	1.64

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2023) EBITDA data.

Sino Biopharmaceutical (FRA:SMZ1) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Sino Biopharmaceutical Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Sino Biopharmaceutical (FRA:SMZ1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (FRA:SMZ1) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

SBHMY:USA SBMFF:USA 01177:Hong Kong SMZ1:Germany

Address

1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG

Website

https://www.sinobiopharm.com

Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.

Sino Biopharmaceutical (FRA:SMZ1) Headlines

No Headlines